BR112021015479A2 - Anticorpos anti-trem1 e métodos relacionados - Google Patents

Anticorpos anti-trem1 e métodos relacionados

Info

Publication number
BR112021015479A2
BR112021015479A2 BR112021015479A BR112021015479A BR112021015479A2 BR 112021015479 A2 BR112021015479 A2 BR 112021015479A2 BR 112021015479 A BR112021015479 A BR 112021015479A BR 112021015479 A BR112021015479 A BR 112021015479A BR 112021015479 A2 BR112021015479 A2 BR 112021015479A2
Authority
BR
Brazil
Prior art keywords
trem1
related methods
trem1 antibodies
antibodies
methods
Prior art date
Application number
BR112021015479A
Other languages
English (en)
Inventor
Aritra Pal
Christopher Chan
G Presta Leonard
Linda Liang
Tu Le Tiep
Venkataraman Sriram
Original Assignee
Pionyr Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pionyr Immunotherapeutics Inc filed Critical Pionyr Immunotherapeutics Inc
Publication of BR112021015479A2 publication Critical patent/BR112021015479A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

anticorpos anti-trem1 e métodos relacionados. são fornecidos aqui anticorpos anti-trem1 e métodos relacionados de produção e uso de anticorpos anti-trem1. também são fornecidos métodos e composições para intensificar uma resposta imune e / ou para o tratamento de uma condição relacionada ao sistema imunológico em um indivíduo, por exemplo, câncer, compreendendo matar, desativar ou esgotar células mieloides não estimulatórias usando um anticorpo anti-trem1 ou fragmento de ligação ao antígeno do mesmo.
BR112021015479A 2019-02-06 2020-02-06 Anticorpos anti-trem1 e métodos relacionados BR112021015479A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962802161P 2019-02-06 2019-02-06
US201962889994P 2019-08-21 2019-08-21
PCT/US2020/016949 WO2020163564A2 (en) 2019-02-06 2020-02-06 Anti-trem1 antibodies and related methods

Publications (1)

Publication Number Publication Date
BR112021015479A2 true BR112021015479A2 (pt) 2021-12-28

Family

ID=71947128

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021015479A BR112021015479A2 (pt) 2019-02-06 2020-02-06 Anticorpos anti-trem1 e métodos relacionados

Country Status (18)

Country Link
EP (1) EP3921344A4 (pt)
JP (1) JP7492522B2 (pt)
KR (1) KR20210126638A (pt)
CN (1) CN113748132A (pt)
AU (1) AU2020218525A1 (pt)
BR (1) BR112021015479A2 (pt)
CA (1) CA3128053A1 (pt)
CL (1) CL2021002075A1 (pt)
CO (1) CO2021010887A2 (pt)
CR (1) CR20210462A (pt)
DO (1) DOP2021000165A (pt)
IL (1) IL284818A (pt)
MX (1) MX2021009500A (pt)
PE (1) PE20212269A1 (pt)
SG (1) SG11202108570SA (pt)
TW (1) TW202037613A (pt)
WO (1) WO2020163564A2 (pt)
ZA (1) ZA202210284B (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014086365A1 (en) * 2012-12-03 2014-06-12 Rigshospitalet Anti-pad2 antibodies and treatment of autoimmune diseases
ES2786651T3 (es) * 2015-02-19 2020-10-13 Compugen Ltd Anticuerpos anti-PVRIG y métodos de uso
CA3012720C (en) * 2016-01-29 2023-01-31 The Governing Council Of The University Of Toronto Frizzled5 protein-binding agents
WO2017152102A2 (en) * 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
CN117562992A (zh) * 2016-04-15 2024-02-20 伊穆奈克斯特股份有限公司 抗人vista抗体及其用途

Also Published As

Publication number Publication date
AU2020218525A1 (en) 2021-09-23
ZA202210284B (en) 2023-03-29
TW202037613A (zh) 2020-10-16
IL284818A (en) 2021-08-31
CL2021002075A1 (es) 2022-04-01
MX2021009500A (es) 2021-09-08
JP2022523145A (ja) 2022-04-21
JP7492522B2 (ja) 2024-05-29
CN113748132A (zh) 2021-12-03
DOP2021000165A (es) 2021-09-30
KR20210126638A (ko) 2021-10-20
WO2020163564A3 (en) 2020-09-24
PE20212269A1 (es) 2021-11-30
CO2021010887A2 (es) 2021-09-09
WO2020163564A2 (en) 2020-08-13
SG11202108570SA (en) 2021-09-29
CA3128053A1 (en) 2020-08-13
CR20210462A (es) 2021-12-13
EP3921344A4 (en) 2022-10-12
EP3921344A2 (en) 2021-12-15

Similar Documents

Publication Publication Date Title
PH12020550860A1 (en) Anti-trem2 antibodies and related methods
MX2021014448A (es) Modulacion de celulas mieloides estimulantes y no estimulantes.
BR112019008010A2 (pt) anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA202091859A1 (ru) Применение антител к sirpa v1 человека и способ получения антител к sirpa v1
AR111362A1 (es) Anticuerpos anti-ilt4 y fragmentos de unión a antígeno
BR112018072485A2 (pt) proteínas de ligação biespecíficas e usos das mesmas
EA201891435A1 (ru) Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47
BR112019007714A2 (pt) anticorpos de 4-1bb anti-humanos e usos dos mesmos
BR112018006531A2 (pt) proteína isolada de ligação ao antígeno (abp), polinucleotídeo isolado, vetor, célula hospedeira, método para produzir uma proteína isolada de ligação ao antígeno (abp), composição farmacêutica, método para tratar ou prevenir uma doença ou condição num sujeito em necessidade deste, método para modular uma resposta imune num indivíduo em necessidade deste e kit
EA202092933A1 (ru) Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
BR112018071287A2 (pt) composições compreendendo coformulação de anticorpos anti-pd-l1 e anti-ctla-4
BR112017019978A2 (pt) anticorpo ou um fragmento de ligação com antígeno, conjugado, receptor de antígeno, cadeia, conjugado de cadeia, proteína de fusão, célula t, polinucleotídeo, vetor, célula ex vivo, método para produzir uma cadeia, método para produzir um anticorpo, composição farmacêutica, método para tratamento de câncer, glicopeptídeo, método para gerar um anticorpo
MX2021005708A (es) Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
EA201791666A1 (ru) Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123
PH12018500663A1 (en) Antigen-binding proteins that activate the leptin receptor
EA202191751A1 (ru) Гуманизированное антитело против pd-1 человека
MX2018013520A (es) Anticuerpos monoclonales de adn dirigidos a moléculas de punto de control.
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
JOP20220030A1 (ar) صيغ مضادة لـ c5 عالية التركيز
EA202092088A1 (ru) Антитела анти-phf-тау и их применение
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин